LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
Recruiting · NCT05886439 · Registry updated 2025-12-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-12-08 | NCT05886439 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | China | 71 |